412 related articles for article (PubMed ID: 25851632)
1. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.
Ravaud A; Barrios CH; Alekseev B; Tay MH; Agarwala SS; Yalcin S; Lin CC; Roman L; Shkolnik M; Anak O; Gogov S; Pelov D; Louveau AL; Melichar B
Ann Oncol; 2015 Jul; 26(7):1378-84. PubMed ID: 25851632
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
[TBL] [Abstract][Full Text] [Related]
3. Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.
Decker T; Söling U; Hahn A; Maintz C; Kurbacher CM; Vehling-Kaiser U; Sent D; Klare P; Hagen V; Chiabudini M; Falkenstein J; Indorf M; Runkel E; Potthoff K
BMC Cancer; 2020 Apr; 20(1):286. PubMed ID: 32252684
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
[TBL] [Abstract][Full Text] [Related]
5. A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.
Melichar B; Bracarda S; Matveev V; Alekseev B; Ivanov S; Zyryanov A; Janciauskiene R; Fernebro E; Mulders P; Osborne S; Jethwa S; Mickisch G; Gore M; van Moorselaar RJ; Staehler M; Magne N; Bellmunt J;
Ann Oncol; 2013 Sep; 24(9):2396-402. PubMed ID: 23803225
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
Escudier B; Bellmunt J; Négrier S; Bajetta E; Melichar B; Bracarda S; Ravaud A; Golding S; Jethwa S; Sneller V
J Clin Oncol; 2010 May; 28(13):2144-50. PubMed ID: 20368553
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
Bukowski RM; Kabbinavar FF; Figlin RA; Flaherty K; Srinivas S; Vaishampayan U; Drabkin HA; Dutcher J; Ryba S; Xia Q; Scappaticci FA; McDermott D
J Clin Oncol; 2007 Oct; 25(29):4536-41. PubMed ID: 17876014
[TBL] [Abstract][Full Text] [Related]
8. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
J Clin Oncol; 2010 May; 28(13):2137-43. PubMed ID: 20368558
[TBL] [Abstract][Full Text] [Related]
9. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.
Bracarda S; Bellmunt J; Melichar B; Négrier S; Bajetta E; Ravaud A; Sneller V; Escudier B
BJU Int; 2011 Jan; 107(2):214-9. PubMed ID: 20942831
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study.
Schultze-Seemann W; Schulz H; Tschechne B; Häckl M
Anticancer Res; 2019 Feb; 39(2):875-882. PubMed ID: 30711970
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
[TBL] [Abstract][Full Text] [Related]
12. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.
Summers J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2010; 15(1):104-11. PubMed ID: 20061402
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
[TBL] [Abstract][Full Text] [Related]
15. Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.
Feldman DR; Ged Y; Lee CH; Knezevic A; Molina AM; Chen YB; Chaim J; Coskey DT; Murray S; Tickoo SK; Reuter VE; Patil S; Xiao H; Aghalar J; Apollo AJ; Carlo MI; Motzer RJ; Voss MH
Cancer; 2020 Dec; 126(24):5247-5255. PubMed ID: 32975815
[TBL] [Abstract][Full Text] [Related]
16. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Knox JJ; Barrios CH; Kim TM; Cosgriff T; Srimuninnimit V; Pittman K; Sabbatini R; Rha SY; Flaig TW; Page RD; Beck JT; Cheung F; Yadav S; Patel P; Geoffrois L; Niolat J; Berkowitz N; Marker M; Chen D; Motzer RJ
Ann Oncol; 2017 Jun; 28(6):1339-1345. PubMed ID: 28327953
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
[TBL] [Abstract][Full Text] [Related]
18. RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis.
Yang L; Alyasova A; Ye D; Ridolfi A; Dezzani L; Motzer RJ
BMC Cancer; 2018 Feb; 18(1):195. PubMed ID: 29454306
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma.
Frampton JE; Keating GM
BioDrugs; 2008; 22(2):113-20. PubMed ID: 18345708
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Ou SS; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
J Clin Oncol; 2008 Nov; 26(33):5422-8. PubMed ID: 18936475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
